Antimalarials linked to retinal toxicity

Article

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight,

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight, according to a recent study published in the Archives of Ophthalmology.

The clinical findings suggested doctors should consider patient's body weight before administering either of the anti-malarial treatments. Dr Micheal Michaelides, et al, Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA, studied 16 women aged between 44–85 for 7 years.

The research was carried out using fundus photography, visual field testing and electrophysiologic assessment on all patients. Six patients received spectral domain optical coherence tomography (OCT) and 4 patients received fundus autofluorescence imaging.

Results indicated that all patients had bilateral macular cone dysfunction. The most common symptom observed was difficulty reading and the fundus results varied from mild retinal pigment epithelial changes to bull's-eye maculopathy.

To lower the risk of retinal toxicity the findings advise the consideration of the patient's lean bodyweight when calculating the daily dosage of hydroxychloroquine sulphate and chloroquine phosphate.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.